GLYC
Price
$0.26
Change
+$0.01 (+4.00%)
Updated
Apr 25, 04:58 PM (EDT)
Capitalization
16.17M
6 days until earnings call
IONS
Price
$29.70
Change
+$0.13 (+0.44%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
4.7B
5 days until earnings call
Ad is loading...

GLYC vs IONS

Header iconGLYC vs IONS Comparison
Open Charts GLYC vs IONSBanner chart's image
GlycoMimetics
Price$0.26
Change+$0.01 (+4.00%)
Volume$423
Capitalization16.17M
Ionis Pharmaceuticals
Price$29.70
Change+$0.13 (+0.44%)
Volume$7.69K
Capitalization4.7B
GLYC vs IONS Comparison Chart
Loading...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLYC vs. IONS commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLYC is a StrongBuy and IONS is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (GLYC: $0.25 vs. IONS: $29.57)
Brand notoriety: GLYC and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLYC: 70% vs. IONS: 99%
Market capitalization -- GLYC: $16.17M vs. IONS: $4.7B
GLYC [@Biotechnology] is valued at $16.17M. IONS’s [@Biotechnology] market capitalization is $4.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLYC’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • GLYC’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, both GLYC and IONS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLYC’s TA Score shows that 6 TA indicator(s) are bullish while IONS’s TA Score has 5 bullish TA indicator(s).

  • GLYC’s TA Score: 6 bullish, 3 bearish.
  • IONS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than IONS.

Price Growth

GLYC (@Biotechnology) experienced а +12.42% price change this week, while IONS (@Biotechnology) price change was +4.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

GLYC is expected to report earnings on Jul 30, 2025.

IONS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($4.7B) has a higher market cap than GLYC($16.2M). GLYC YTD gains are higher at: 0.683 vs. IONS (-15.418). GLYC has higher annual earnings (EBITDA): -32.47M vs. IONS (-353.72M). IONS has more cash in the bank: 2.3B vs. GLYC (10.7M). GLYC has less debt than IONS: GLYC (66.8K) vs IONS (1.42B). IONS has higher revenues than GLYC: IONS (705M) vs GLYC (0).
GLYCIONSGLYC / IONS
Capitalization16.2M4.7B0%
EBITDA-32.47M-353.72M9%
Gain YTD0.683-15.418-4%
P/E RatioN/AN/A-
Revenue0705M-
Total Cash10.7M2.3B0%
Total Debt66.8K1.42B0%
FUNDAMENTALS RATINGS
GLYC vs IONS: Fundamental Ratings
GLYC
IONS
OUTLOOK RATING
1..100
3111
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
6281
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLYC's Valuation (87) in the Biotechnology industry is in the same range as IONS (96). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

GLYC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IONS (100). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

IONS's SMR Rating (95) in the Biotechnology industry is in the same range as GLYC (97). This means that IONS’s stock grew similarly to GLYC’s over the last 12 months.

GLYC's Price Growth Rating (62) in the Biotechnology industry is in the same range as IONS (81). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

IONS's P/E Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for GLYC (100). This means that IONS’s stock grew somewhat faster than GLYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLYCIONS
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
61%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 10 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPVM55.600.78
+1.42%
Invesco S&P 500 Value with Momentum ETF
RORO15.240.19
+1.26%
ATAC US Rotation ETF
FDT60.370.70
+1.17%
First Trust Dev Mkts Ex-US AlphaDEX® ETF
RWR94.980.33
+0.35%
SPDR® Dow Jones® REIT ETF
FJP54.79-0.04
-0.07%
First Trust Japan AlphaDEX® ETF

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
+5.03%
LYRA - GLYC
75%
Closely correlated
+7.02%
EYPT - GLYC
47%
Loosely correlated
-2.53%
AXON - GLYC
36%
Loosely correlated
+2.39%
IONS - GLYC
35%
Loosely correlated
+1.62%
MDGL - GLYC
34%
Loosely correlated
+3.61%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+1.62%
ALNY - IONS
52%
Loosely correlated
+0.26%
IDYA - IONS
48%
Loosely correlated
+1.33%
RARE - IONS
47%
Loosely correlated
+0.88%
RCKT - IONS
47%
Loosely correlated
+4.06%
XENE - IONS
47%
Loosely correlated
+1.62%
More